Skip to main content
Equibles
CTNM logo

CTNM · Contineum Therapeutics, Inc.

Track CTNM — free

Use CTNM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CTNM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.82 +0.16 (+1.09%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$557.55M
Shares
37.62M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.82 Open$14.94 Day$14.62–15.24 52W close$9.17–17.57 Avg vol 30d483K Short int2.3M · 6.2% float · 4.0d Short vol65% Last earningsOct 30, 2025 DataApr 2024–Sep 2026 Filing10-Q · Jul 30

Up next

Latest filing: 10-Q
filed Jul 30, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$57.56M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-9.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$236.55M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+44.7%
Year over year · more shares
Price change (1Y)
+24.3%
Trailing year
Short interest
6.2%
Latest settlement · 4.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +9%
above
Price vs 50-day avg −3%
below
RSI (14) 43
neutral
MACD trend Negative
52-week position 67%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Strong
1-month return −3%
trailing
6-month return +21%
trailing
YTD return +30%
this year
Relative strength +4%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $15 › 200d $14 — 50d above 200d
Institutional flow Accumulating
+13% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.22% of float · ▲ +0.2% MoM · 4.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
102 holders — near 2-yr high, broad support
Squeeze score 67
elevated · 0–100
Fundamentals
Poor
Revenue growth −100%
Y/Y
EPS growth +0%
Y/Y
Free cash flow $-55.5M
Quant / Vol
risk profile
Very High
Volatility 67%
annualized · 1-yr
Max drawdown −30%
past year
ATR 6.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+9% Bullish
Price vs 50-day avg
−3% Neutral
RSI (14)
43 Neutral
MACD trend
Negative Bearish
52-week position
67% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $15 › 200d $14 — 50d above 200d
Institutional flow Accumulating
+13% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.22% of float · ▲ +0.2% MoM · 4.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
102 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $9 Now $15 · 67% Range high $18
vs 200-day avg +9% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CTNM
Contineum Therapeutics, Inc.
this stock
$557.55M +29.7% -100.0% — 6.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
102
% held
81.2%
Net QoQ
-6.6K sh
Top holder
SUVRETTA CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
87
View
Short & Settlement
Short Interest Rising
Shares short
2.3M
Days to cover
4.0d
Change
+4.2K sh
View
Short Volume
Short vol %
65%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
46
Value
$704
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
49.7%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-60.0M
EPS diluted
$-2.17
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 30, 2026
This year
12
View
Proposed Sales
Value
$41.8K
Shares
2.5K
Filed
Sep 8, 2026
View
Earnings & Events
Earnings Calls
Last call
Jun 9, 2026
View

Performance

5D 20D 120D MTD YTD
CTNM -15.7% -3.1% +21.4% -8.7% +29.7%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -14.5% -1.4% +3.5% -8.4% +17.6%
Key facts CIK 1855175 CUSIP 21217B100 13F (30d) 71 filings 71 filers Visit website Investor relations